Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. | Beigelman et al. Respiratory Research 2010 11 90 http content 11 1 90 RESPIRATORY RESEARCH RESEARCH Open Access Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis Avraham Beigelman 1 Cassandra L Mikols2 Sean P Gunsten2 Carolyn L Cannon1 Steven L Brody2 and Michael J Walter2 Abstract Background Viral bronchiolitis is the leading cause of hospitalization in young infants. It is associated with the development of childhood asthma and contributes to morbidity and mortality in the elderly. Currently no therapies effectively attenuate inflammation during the acute viral infection or prevent the risk of post-viral asthma. We hypothesized that early treatment of a paramyxoviral bronchiolitis with azithromycin would attenuate acute and chronic airway inflammation. Methods Mice were inoculated with parainfluenza type 1 Sendai Virus SeV and treated daily with PBS or azithromycin for 7 days post-inoculation. On day 8 and 21 we assessed airway inflammation in lung tissue and quantified immune cells and inflammatory mediators in bronchoalveolar lavage BAL . Results Compared to treatment with PBS azithromycin significantly attenuated post-viral weight loss. During the peak of acute inflammation day 8 azithromycin decreased total leukocyte accumulation in the lung tissue and BAL with the largest fold-reduction in BAL neutrophils. This decreased inflammation was independent of changes in viral load. Azithromycin significantly attenuated the concentration of BAL inflammatory mediators and enhanced resolution of chronic airway inflammation evident by decreased BAL inflammatory mediators on day 21. Conclusions In this mouse model of paramyxoviral bronchiolitis azithromycin attenuated acute and chronic airway inflammation. These findings demonstrate anti-inflammatory effects of azithromycin that are not related to anti-viral activity. Our findings support the rationale for future prospective randomized clinical trials that will
